# References

### References & Information

#### 1  
A. C. Andersen. _The beagle as an experimental dog_. Iowa State University Press. University of Michigan. 616 pages. 1970.

#### 2
N. Balakrishnan (Editor). _Methods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential MethodsArticle Title_. John Wiley and Sons. . 2014.

#### 3
L. Baxter, H. Zhu, D. Mackensen, and R. Jain. _Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice_. Cancer Research. 54. 1517-28. 1994.

#### 4
L.Z. Benet. _Basic Principles and Its Use as a Tool in Drug Metabolism_. in: Drug Metabolism and Drug Toxicity. J.R. Mitchell. M.G. Horning. Raven Press. New York, USA. pp. 199. 1984.

#### 5
L.M. Berezhkovskiy. _Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination_. Journal of Pharmaceutical Sciences. 93(6). 1628-40. 2004.

#### 6
A. C. Hindmarsh, P. N. Brown, K. E. Grant, S. L. Lee, R. Serban, D. E. Shumaker, and C. S. Woodward. _[SUNDIALS: Suite of Nonlinear and Differential/Algebraic Equation Solvers](https://computing.llnl.gov/projects/sundials)_. ACM Transactions on Mathematical Software, 31(3), pp. 363-396, 2005.

#### 7
P. Costa and J. M. Sousa Lobo. _Modeling and comparison of dissolution profiles_. Eur J Pharm Sci. 13(2). 123-33. 2001.

#### 8
C. Crone and D.G. Levitt. _Capillary permeability to small solutes_. in Handbook of Physiology: The Cardiovascular System: Microcirculation. E.M. Renkin. C.C. Michel. American Physiological Society. Bethesda, MD, USA. pp. 411–466. 1984.

#### 9
C. Dordas and P. H. Brown. _Permeability of Boric Acids across Lipid Bilayers and Factors Affecting it_. Journal of Membrane Biology. 175. 95-105. 2000.

#### 10
J.B. Dressman, K. Thelen, and E. Jantratid. _Towards Quantitative Prediction of Oral Drug Absorption_. Clinical Pharmacokinetics. 47(10). 655-67. 2008.

#### 11
A. N. Edginton, S. Willmann, B. Voith, and W. Schmitt. _A mechanistic approach to the scaling of clearance in children_. Clinical Pharmacokinetics. 45. 683-704. 2006.

#### 12
A. N. Edginton, W. Schmitt, and S. Willmann. _Application of physiology-based pharmacokinetic and pharmacodynamic modeling_ towards individualized propofol target controlled infusion. Advances in Therapy. 23. 143-158. 2006.

#### 13
A. N. Edginton, W. Schmitt, and S. Willmann. _Development and evaluation of a generic physiologically based pharmacokinetic model for children_. Clinical Pharmacokinetics. 45. 1013-1034. 2006.

#### 14
A. N. Edginton, F.P. Theil, W. Schmitt, and S. Willmann. _Whole body physiologically-based pharmacokinetic models: their use in clinical drug development_. Expert Opinion on Drug Metabolism & Toxicology. 4(9). 1143-52. 2008.

#### 15
A.N. Edginton, G. Ahr, S. Willmann, and H. Stass. _Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling_. Clinical Pharmacokinetics. 48(3). 181-7. 2009.

#### 16
A. N. Edginton and G. Joshi. _Have physiologically-based pharmacokinetic models delivered?_. Expert Opin Drug Metab Toxicol. 929-34. 7(8). 2011.

#### 17
A. N. Edginton and S. Willmann. _Physiology-based simulations of a pathological condition : prediction of pharmacokinetics in patients with liver cirrhosis_. Clinical Pharmacokinetics. 47(11). 743-52. 2008.

#### 18
T. Eissing, L. Kuepfer, C. Becker, M. Block, K. Coboeken, T. Gaub, L. Goerlitz, J. Jaeger, R. Loosen, B. Ludewig, M. Meyer, C. Niederalt, M. Sevestre, H. U. Siegmund, J. Solodenko, K. Thelen, U. Telle, W. Weiss, T. Wendl, S. Willmann, and J. Lippert. _A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks_. Front Physiol. 4. 2. 2011.

#### 19
T. Eissing, J. Lippert, and S. Willmann. _Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide: Model-Based Analysis of the Influence of CYP2D6 Activity, UGT2B7 Activity, Renal Impairment, and CYP3A4 Inhibition_. Mol Diagn Ther. 43-53. 16(1). 2012.

#### 20
C.T. Ekstrom (Editor). _Introduction to Statistical Data Analysis for the Life Sciences, Second Edition_. CRC Press. . 2014.

#### 21
B. I. Escher and R. P. Schwarzenbach. _Partitioning of Substituted Phenols in Liposome-Water, Biomembrane-Water, and Octanol-Water Systems_. Environmental Science and Technology. 30. 260-270. 1996.

#### 22
P. Espie, D. Tytgat, M. L. Sargentini-Maier, I. Poggesi, and J. B. Watelet. _Physiologically based pharmacokinetics (PBPK)_. Drug Metab Rev. 41. 391-407. 2009.

#### 23
L. Fahrmeir, T. Kneib, and S. Lang. _Regression Modelle, Methoden und ihre Anwendung_. Springer Verlag. . 2009.

#### 24
F. Frezard and A. Garnier-Suillerot. _Permeability of Lipid Bilayer to Anthracycline Derivates. Role of the Bylayer Composition and of the Temperature_. Biochimica et Biophysica Acta. 1389. 13-22. 1998.

#### 25
E. Galia, E. Nicolaides, D. Härter, R. Läbenberg, C. Reppas, and J. B. Dressman. _Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs_. Pharmaceutical Research. 15. 698-705. 1998.

#### 26
A. Garg and J. Balthasar. _Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice_. Journal of Pharmacokinetics and Pharmacodynamics.. 34. 687-709. 2007.

#### 27
Henri P. Gavin. _The Levenberg-Marquardt method for nonlinear least squares curve-fitting problems_. https://people.duke.edu/%7Ehpgavin/ https://people.duke.edu/~hpgavin/ce281/lm.pdf. . . 2016.

#### 28
X. Ge, S. Yamamoto, S. Tsutsumi, Y. Midorikawa, S. Ihara, S. M. Wang, and H. Aburatani. _Interpreting expression profiles of cancers by genome- wide survey of breadth of expression in normal tissues_. Genomics.. 86(2). 127-41. 2005.

#### 29
R. Gebhardt. _Metabolic zonation of the liver: Regulation and implications for liver function_. Pharmacol. Ther.. 53(3). 275-354. 1992.

#### 30
J. A. Goldsmith, N. Randall, and S. D. Ross. _On methods of expressing dissolution rate data._. J Pharm Pharmacol.. 30(6). 347-9. 1978.

#### 31
H. W. Haagard. _The Absorption, Distribution and Elimination of Ethyl Ether_. The Journal of Biological Chemistry. 59. 753-770. 1924.

#### 32
M. W. Härter, J. Keldenich, and W. Schmitt. in Handbook of Combinatorial Chemistry. Vol. 2. K. C. Nicholaou. R. Hanko. W. Hartwig. Wiley-VCH. Weinheim, Germany. 2002.

#### 33
W. L. Hayton. _Maturation and Growth of Renal Function: Dosing Renally Cleared Drugs in Children_. AAPS PharmSci. 2(1). E3. 2002.

#### 34
P. Holliger and P. J. Hudson. _Engineered antibody fragments and the rise of single domains_. Nat Biotechnol.. 23(9). 1126-36. 2005.

#### 35
H. G. Holzhutter, D. Drasdo, T. Preusser, J. Lippert, and A. M. Henney. _The virtual liver: a multidisciplinary, multilevel challenge for systems biology_. Wiley Interdiscip Rev Syst Biol Med. 2012.

#### 36
R. Kawei, M. Lemaire, J. L. Steimer, A. Bruelisauer, W. Niederberger, and M. Rowland. _Physiology Based Pharmacokinetic Study on a Cyclosporin Derivate, SDZ IMM 125_. Journal of Pharmacokinetics and Biopharmaceutics. 22. 327-365. 1994.

#### 37
G. Kersting, S. Willmann, G. Wurthwein, J. Lippert, J. Boos, and G. Hempel. _Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children_. Cancer Chemother Pharmacol. 397-405. 69(2). 2012.

#### 38
B. Krippendorf, R. Neuhaus, and P. Lienau. _Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values_. J. of Biomolecular Screening. 14((8). 2009.

#### 39
L. Kuepfer, J. Lippert, and T. Eissing. _Multiscale mechanistic modeling in pharmaceutical research and development_. Adv Exp Med Biol. 543-61. 736. 2012.

#### 40
F. Langenbucher. _Linearization of dissolution rate curves by the Weibull distribution_. J Pharm Pharmacol.. 24(12). 979-81. 1972.

#### 41
D. G. Levitt. _Physiologically based pharmacokinetic modeling of arterial- antecubital vein concentration difference_. BMC Clinical Pharmacology. 4. 2. 2004.

#### 42
E. D. Lobo, R. J. Hansen, and J. P. Balthasar. _Antibody Pharmacokinetics and Pharmacodynamics_. J. Pharm. Sci.. 93(11). 2645-2668. 2004.

#### 43
A. Loidl-Stahlhofen, T. Hartmann, M. Schöttner, C. Röhring, H. Brodowsky, J. Schmitt, and J. Keldenich. _Multilamellar Liposomes and Solid- Supported Lipid Membranes (TRANSIL): Screening of Lipid-Water Partitioning Toward a High-Throughput Scale_. Pharmaceutical Research. 18. 1782-1788. 2001.

#### 44
G. Loizou, M. Spendiff, H.A. Barton, J. Bessems, F.Y. Bois, M.B. d'Yvoire, H. Buist, H.J. Clewell 3rd, B. Meek, U. Gundert-Remy, G. Goerlitz, and W. Schmitt. _Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps_. Regulatory Toxicology and Pharmacology. 50(3). 400-11. 2008.

#### 45
K. Madsen, H.B. Nielsen, and O. Tingleff. _METHODS FOR NON- LINEAR LEAST SQUARES PROBLEMS_. http://www2.imm.dtu.dk/ http://www2.imm.dtu.dk/pubdb/views/edoc_download.php/3215/pdf/imm3215.pdf. . . April 2004.

#### 46
M. Meyer, S. Schneckener, B. Ludewig, L. Kuepfer, and J. Lippert. _Using expression data for quantification of active processes in physiologically- based pharmacokinetic modeling_. Drug Metab Dispos. 2012.

#### 47
John A. Nelder and R. Mead. _A simplex method for function minimization_. Computer Journal. 7. 308-313. 1965.

#### 48
I. Nestorov. _Whole-body physiologically based pharmacokinetic models_. Exp Opin Drug Metab Toxicol. 3. 235-249. 2007.

#### 49
M. Nishimura, H. Yaguti, H. Yoshitsugu, S. Naito, and T. Satoh. _Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR_. Yakugaku Zasshi.. 123(5). 369-75. 2003.

#### 50
M. Nishimura and S. Naito. _Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies_. Drug Metab Pharmacokinet. 20(6). 452-77. 2005.

#### 51
M. Nishimura and S. Naito. _Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes_. Drug Metab Pharmacokinet. 21(5). 357-74. 2006.

#### 52
P. Poulin, K. Schoenlein, and F.P. Theil. _Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs_. Journal of Pharmaceutical Sciences. 90(4). 436-47. 2001.

#### 53
P. Poulin and F. P. Theil. _A Priori Prediction of Tissue: Plasma Partition Coefficients of Drugs to Facilitate the Use of Physiologically-Based Pharmacokinetic Models in Drug Discovery_. Journal of Pharmaceutical Sciences. 89. 16-35. 2000.

#### 54
P. Poulin and F.P. Theil. _Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution_. Journal of Pharmaceutical Sciences. 91(1). 129-56. 2002.

#### 55
P. Poulin and F.P. Theil. _Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition_. Journal of Pharmaceutical Sciences. 91(5). 1358-70. 2002.

#### 56
NJ. Proctor, GT. Tucker, and A. Rostami-Hodjegan. _Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors._. Xenobiotica. 34(2). 151-78. 2004.

#### 57
B. Rippe and B. Haraldsson. _Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations_. Acta Physiol Scand.. 131(3). pp 411-28. 1987.

#### 58
B. Rippe and B. Haraldsson. _Transport of macromolecules across microvascular walls: the two-pore theory_. Am Physiological Soc.. 74. pp 163-219. 1994.

#### 59
T. Rodgers, D. Leahy, and M. Rowland. _Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases_. Journal of Pharmaceutical Sciences. 94. 1259-1275. 2005.

#### 60
T. Rodgers, D. Leahy, and M. Rowland. _Tissue Distribution of Basic Drugs: Accounting for Enantiomeric, Compound and Regional Differences Amongst beta-Blocking Drugs in Rat_. Journal of Pharmaceutical Sciences. 94. 1237-1248. 2005.

#### 61
T. Rodgers and M. Rowland. _Physiologically Based Pharmacokinetic Modeling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions_. Journal of Pharmaceutical Sciences. 95. 1238-1257. 2006.

#### 62
T. Rodgers and M. Rowland. _Mechanistic Approaches to Volume of Distrubtion Predictions: Understanding the Processes_. Pharmaceutical Research. 24. 918-933. 2007.

#### 63
AD. Rodrigues. _Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes_. Biochem Pharmacol. 465-80. 57 (5). 1999.

#### 64
A. Rostami-Hodjegan and GT. Tucker. _Simulation and prediction of in vivo drug metabolism in human populations from in vitro data._. Nat Rev Drug Discov. 6(2). 140-8. 2007.

#### 65
M. Rowland and T.N. Tozer. _Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications_. 4th edition. D.B. Troy. Lippincott Williams and Wilkins. Philadelphia, PA 19106. pp. 199. 1984.

#### 66
T. Sawamato, S. Haruta, Y. Kurosaki, K. Higaki, and T. Kimura. _Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability_. Journal of Pharmaceutical Pharmacology. 49. 450-457. 1997.

#### 67
J. Schlender. A manuscript including the description of the physiology base of the Japanese population implemented in PK-Sim® is in preparation..

#### 68
W. Schmitt. _General approach for the calculation of tissue to plasma partition coefficients_. Toxicology In Vitro. 22(2). 457-67. 2008.

#### 69
W. Schmitt and S. Willmann. _Physiology-based pharmacokinetic modeling: ready to be used_. Drug Discov Today. 2. 125-132. 2005.

#### 70
L. F. Shampine and S. Willmann. _Solving ODEs and DDEs with residual control_. Appl. Num. Math.. 52. 113-127. 2005.

#### 71
P. Sidhu, H. T. Peng, B. Cheung, and A. Edginton. _Simulation of differential drug pharmacokinetics under heat and exercise stress using a physiologically based pharmacokinetic modeling approach_. Can J Physiol Pharmacol. 365-82. 89(5). 2011.

#### 72
R.B. Silvermann. _Mechanism-based enzyme inhibitors_. Methods in Enzymology. 249. 1995.

#### 73
A. Strougo, T. Eissing, A. Yassen, S. Willmann, M. Danhof, and J. Freijer. _First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development_. J Pharmacokinet Pharmacodyn. 2012.

#### 74
G. Tanaka and H. Kawamura. _Anatomical and physiological characteristics for Asian reference man: Male and female of different ages: Tanaka model_. Division of Radioecology. National Institute of Radiological Sciences. Hitachinaka 311-12 Japan. Report Number NIRS-M-115. 1996.

#### 75
A. Terenji, S. Willmann, J. Osterholz, P. Hering, and H. J. Schwarzmaier. _Measurement of the coagulation dynamics of bovine liver using the modified microscopic Beer-Lambert law_. Lasers Surg Med. 365-70. 36(5). 2005.

#### 76
F. P. Theil, T. W. Guentert, S. Haddad, and P. Poulin. _Utility of Physiologically Based Pharmacokinetic Models to Drug Development and Rational Drug Discovery Candidate Selection_. Toxicology Letters. 138. 29-49. 2003.

#### 77  
K. Thelen and J.B. Dressman. _Cytochrome P450-mediated metabolism in the human gut wall_. Journal of Pharmacokinetics and Pharmacodynamics. 61(5). 541-58. 2009.

#### 78
K. Thelen, E. Jantratid, J. B. Dressman, J. Lippert, and S. Willmann. _Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing_. J Pharm Sci. 2899-904. 99(6). 2010.

#### 79
K. Thelen, K. Coboeken, S. Willmann, R. Burghaus, J. B. Dressman, and J. Lippert. _Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions_. J Pharm Sci. 5324-45. 100(12). 2011.

#### 8
K. Thelen, K. Coboeken, S. Willmann, J. B. Dressman, and J. Lippert. _Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms_. J Pharm Sci. 1267-80. 101(3). 2012.

#### 81
K. Thelen, K. Coboeken, J. B. Dressman, and S. Willmann. _Dynamically simulating the effect of food on gastric emptying using a detailed_ physiological model for gastrointestinal transit and absorption.. PAGE meeting 2012. Venice, Italy. 2012.

#### 82
Third National Health and Nutrition Examination Survey, (NHANES III). 1997\. National Center for Health Statistics Hyattsville, MD 20782 http://www.cdc.gov/nchs/nhanes.htm

#### 83
Expressed Sequence Tags (EST) from UniGene. 2010\. National Center for Biotechnology Information (NCBI) https://ftp.ncbi.nlm.nih.gov/repository/UniGene/

#### 84
Annals of the ICRP. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. J. Valentin. Vol. 32 (3-4). 2002.

#### 85
P. H. van der Graaf and N. Benson. _Systems pharmacology: bridging systems biology and pharmacokineticspharmacodynamics (PKPD) in drug discovery and development_. Pharm Res. 1460-4. 28(7). 2011.

#### 86
B. van Ommen, J. de Jongh, J. van de Sandt, B. Blaauboer, E. Hissink, J. Bogaards, and P. Bladeren. _Computer-aided Biokinetic Modelling Combined with In Vitro Data_. Toxicology In Vitro. 9. 537-542. 1995.

#### 87
M. Vossen, M. Sevestre, C. Niederalt, I. J. Jang, S. Willmann, and A. N. Edginton. _Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models_. Theor Biol Med Model. 13. 4. 2007.

#### 88
W. Wang, E. Q. Wang, and J.P. Balthasar. _Monoclonal Antibody Pharmacokinetics and Pharmacodynamics_. Clin Pharmacol Ther.. 548-58. 84(5). 2008.

#### 89
O. Weber, S. Willmann, H. Bischoff, V. Li, A. Vakalopoulos, K. Lustig, F. T. Hafner, R. Heinig, C. Schmeck, and K. Buehner. _Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling_. Br J Clin Pharmacol. 219-31. 73(2). 2012.

#### 90
S. Willmann, H. J. Schwarzmaier, A. Terenji, I. V. Yaroslavsky, and P. Hering. _Quantitative microspectrophotometry in turbid media_. Appl Opt. 4904-13. 38(22). 1999.

#### 91
S. Willmann, A. Terenji, H. Busse, I. V. Yaroslavsky, A. N. Yaroslavsky, H. J. Schwarzmaier, and P. Hering. _Scattering delay time of Mie scatterers determined from steady-state and time-resolved optical spectroscopy_. J Opt Soc Am A Opt Image Sci Vis. 745-9. 17(4). 2000.

#### 92
S. Willmann, J. Lippert, M. Sevestre, J. Solodenko, F. Fois, and W. Schmitt. PK-Sim®: A physiologically based pharmacokinetic 'whole-body' model. Biosilico. 1. 121-124. 2003.

#### 93
S. Willmann, W. Schmitt, J. Keldenich, and J. B. Dressman. _A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats_. Pharmaceutical Research. 20. 1766-1771. 2003.

#### 94
S. Willmann, A. Terenji, J. Osterholz, J. Meister, P. Hering, and H.J. Schwarzmaier. _Small-volume frequency-domain oximetry: phantom experiments and first in vivo results_. J Biomed Opt. 618-28. 8(4). 2003.

#### 95
S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J. B. Dressman. _A Physiological Model for the Estimation of Fraction Dose Absorbed in Humans_. Journal of Medical Chemistry. 47. 4022-4031. 2004.

#### 96
S. Willmann, J. Lippert, and W. Schmitt. _From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools_. Expert Opinion on Drug Metabolism and Toxicology. 1. 159-168. 2005.

#### 97
S. Willmann, K. Hoehn, A. N. Edginton, M. Sevestre, J. Solodenko, W. Weiss, J. Lippert, and W. Schmitt. _Development of a physiologically-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs_. Journal of Pharmacokinetics and Pharmacodynamics. 34(3). 401-431. 2007.

#### 98
S. Willmann, A.N. Edginton, and J.B. Dressman. _Development and validation of a physiology-based model for the prediction of oral absorption in monkeys_. Pharmaceutical Research. 24(7). 1275-82. 2007.

#### 99
S. Willmann, A.N. Edginton, M. Kleine-Besten, E. Jantratid, K. Thelen, and J.B. Dressman. _Whole-Body Physiologically-Based Pharmacokinetic Population Modelling of Oral Drug Administration: Inter-Individual Variability of Cimetidine Absorption_. Journal of Pharmacokinetics and Pharmacodynamics. 61. 891-9. 2009.

#### 100
S. Willmann, A.N. Edginton, K. Coboeken, G. Ahr, and J. Lippert. _Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study_. Clinical Pharmacology and Therapeutics. advance online publication. 2009.

#### 101
S. Willmann. _The in silico Child. Can computer simulations replace clinical pharmacokinetic studies?_. Original: Das In-silico-Child. Konnen Computer-Simulationen klinisch-pharmakokinetische Studien ersetzen?. Pharm Unserer Zeit. 62-7. 38(1). 2009.

#### 102
S. Willmann, K. Thelen, C. Becker, J. B. Dressman, and J. Lippert. _Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs_. Eur J Pharm Biopharm. 83-94. 76(1). 2010.

#### 103
Y. Wu and F. Kesisoglou. _Immediate Release Oral Dosage Forms: Formulation Screening in the Pharmaceutical Industry_. in: Oral Drug Absorption: Prediction and Assessment. J. J. Dressman. C. Reppas. Informa Healthcare. New York, USA. pp. 323. 2009.

#### 104
J. Yang, M. Jamei, and K. Rowland Yeo. _Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition_ . European Journal in Pharmaceutical Sciences. 31. 2007.

#### 105
H. Zischka, C. J. Gloeckner, C. Klein, S. Willmann, M. Swiatek-de Lange, and M. Ueffing. _Improved mass spectrometric identification of gel- separated hydrophobic membrane proteins after sodium dodecyl sulfate removal by ion-pair extraction_. Proteomics. 3776-82. 4(12). 2004.

#### 106
[Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. *PBPK models for  CYP3A4 and P‐gp DDI prediction: a modeling network of rifampicin,  itraconazole, clarithromycin, midazolam, alfentanil and digoxin.*](https://www.ncbi.nlm.nih.gov/pubmed/30091221)